Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Stability study services are a core evaluation component for drug substance and drug product quality control. They provide systematic stability assessment to determine shelf life, storage conditions, and packaging requirements, ensuring that product quality, safety, and efficacy are maintained throughout its shelf life. Stability studies bridge product development and commercial manufacturing and are mandatory for IND/BLA CMC sections.
ICH Q5C provides the framework for biotechnological product stability testing, requiring stability‑indicating methods and testing in the final container. ICH Q1A(R2) sets global standards for new drug stability, covering long‑term, accelerated, and intermediate conditions. In April 2025, ICH released a comprehensive revision consolidating Q1A–Q1F and Q5C into a single document, adding new topics such as advanced therapy stability considerations, stability modeling, and reference standard and excipient stability – the first major update in over twenty years.
Creative Biogene provides one‑stop services from protocol design to IND/BLA submission data packages. Testing methods reuse the DS/DP release testing technology platform, and data are ready for CMC sections.
Real‑time stability assessment under recommended storage conditions. For biologics, typically 2‑8°C or -20°C. Long‑term data must cover the entire shelf life – at least 12 months for registration, and up to 36 months for the commercial stage.
The product is placed under harsher conditions to accelerate degradation, predicting behavior under normal storage and supporting temporary approval or emergency use authorization. The Arrhenius model is commonly used to estimate shelf life under long‑term conditions from degradation rate constants observed under accelerated conditions.
Product is exposed to extreme conditions such as heat, oxidation, light, and acid or base hydrolysis to identify intrinsic degradation pathways and degradation products. The core objective is to demonstrate that analytical methods are stability‑indicating – able to detect all potential degradation products.
Mandatory testing to assess light sensitivity of drug substance and drug product. Light exposure can cause chemical degradation, potency loss, harmful degradation products, or appearance changes. ICH Q1B requires exposure to at least 1.2 million lux·hours of visible light and 200 watt·hours per square meter of near UV light in the 320‑400 nm range.
Confirms that the packaging system protects product quality under real shipping conditions. Temperature‑sensitive products such as vaccines and biologics face multiple stresses including vibration, shock, compression, and temperature fluctuations. ISTA and ASTM D4169 provide standardized protocols.
| Document | Section | Key Requirement |
| ICH Q5C | Biotech Stability | Comprehensive protocol, stability‑indicating methods, final container testing |
| ICH Q1A(R2) | New Drug Stability | Storage conditions, duration, climatic zones |
| ICH Q1B | Photostability | ≥1.2M lux·h + ≥200 W·h/m² UV |
| ICH Q1E | Data Evaluation | Regression analysis, 95% confidence intervals |
| ICH Q5C (2025 consolidated) | Stability Testing | Advanced therapies, vaccines, stability modeling |
| ISTA | Package Testing (20, 3A, 3E, etc.) | Transport simulation; 2025 adds 8E hot extreme profile |
| ASTM D4169‑23 | Distribution Simulation | Standard practice for distribution |
For a customized stability study strategy, protocol design, or IND/BLA submission support for your product, contact Creative Biogene's technical team.
Q1: Are stability studies mandatory for all drug products?
A: Yes. Stability studies are required by ICH Q5C for biologics and ICH Q1A(R2) for new drugs, and are a mandatory part of IND/BLA CMC sections. They determine shelf life, storage conditions, and packaging. The 2025 ICH Q1 consolidated guidance extends coverage to advanced therapies (ATMPs), vaccines, and combination products.
Q2: What is the difference between long‑term and accelerated stability?
A: Long‑term stability is real‑time testing under recommended storage conditions (e.g., 5°C ± 3°C) for 12‑36 months – the primary basis for shelf life determination. Accelerated stability is tested under elevated temperatures (e.g., 40°C ± 2°C) for 6 months – used to predict degradation kinetics, support temporary approvals, and identify failure modes. Both require at least three batches tested in final containers.
Q3: How is stability‑indicating method validation performed?
A: Through forced degradation studies. The product is exposed to heat (50°C), oxidative stress (0.1‑0.3% H₂O₂), light (ICH Q1B conditions), and acid or base hydrolysis. The analytical method must detect degradation products with adequate separation from the main peak (resolution ≥1.5). For biologics, SEC‑HPLC for aggregation and peptide mapping or charge variant analysis for deamidation are key to demonstrating stability‑indicating capability.
Copyright © 2026 Creative Biogene. All rights reserved.